Trial reportDrug design, development and therapy2025
Effects of Esketamine on Postoperative Delirium and Postoperative Cognitive Function in Elderly Gastrointestinal Tumor Patients with Preoperative Anxiety.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Effects of esketamine on postoperative delirium in adult patients: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurology · 2026Pooled it
- Esketamine for Postoperative Anxiety After Major Abdominal Tumor Surgery: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Neuroinflammation in postoperative cognitive dysfunction: the multi-target potential of esketamine in modulating microglial responses and synaptic integrity.Frontiers in molecular neuroscience · 2026Review
- Chronic Alcohol Use and Accelerated Brain Aging: Shared Mechanisms with Alzheimer's Disease Pathophysiology.Brain sciences · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study is to investigate the effects of administering low-dose esketamine during anesthesia induction on the occurrence of postoperative delirium (POD) and postoperative cognitive function in elderly patients with preoperative anxiety. Patients and Methods: Elderly patients aged 60-80 years and with preoperative anxiety who were undergoing surgery for gastrointestinal tumors were enrolled. The patients were randomly divided into an esketamine group or a placebo group. Upon intravenous induction of general anesthesia, the placebo group received normal saline, while the esketamine group received a subanesthetic dose (0.25 mg/kg) of esketamine. The primary outcome was the incidence of POD and the Mini-Mental State Examination (MMSE) score within 7 days after the operation (d1 to d7). Secondary outcomes included perioperative hemodynamic adverse events, postoperative anxiety, postoperative pain score, and analgesic consumption. Results: 118 patients were screened for eligibility, and 100 were recruited and analyzed. The incidence of POD within 7 days after surgery in the esketamine group was significantly lower than the placebo group (24.00% vs 48.00%, Conclusion: In elderly patients with preoperative anxiety who undergo gastrointestinal tumor surgery, administering a low-dose intravenous esketamine injection (0.25 mg/kg) during anesthesia induction can decrease the incidence of POD and improve early postoperative cognitive function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.